Looking for the bigger picture:
current challenges & progress in preclinical tools for I–O

Immuno-Oncology Insights 2023; 4(1), 1–6

DOI: 10.18609/ioi.2023.001

Published: 27 February 2023
Pelin Candarlioglu

Róisin McGuigan, Editor, Immuno-Oncology Insights, speaks to Pelin Candarlioglu, Chair of Industry Advisory Board at European Organ On Chip Society (EUROoCS)

Pelin Candarlioglu, PhD, is a tissue engineer by training, having received her PhD in the field from Imperial College London. She moved into oncology during her PostDoc position, working on circulating tumor cells at UCL. Her introduction to organ-on-chip (OoC) was during her leading a Cell Biology/Microfluidics lab in Cambridge at Enplas Corporation where she was developing a microfluidic chip system specifically designed for immuno-oncology applications. Currently, as part of Complex in vitro models (CIVM) group, she is leading a small team utilizing her expertise in microfluidics, tissue engineering and especially OoC to lead multiple initiatives both externally and internally to expand the complex in vitro model portfolio of GSK for immuno-oncology. Pelin is very active on the 3Rs initiative in GSK and supporting the reduce and replacement aspects. She also represents GSK globally in relevant organizations such as NA3RsC MPS Initiative, IQ-MPS, NC3R, OOACT in UK and as chair of industry advisory board at EUROoCS.